

Prostate Cancer Journal Club For Patients

Can Micro-Ultrasound Replace MRI for Prostate Cancer Diagnosis?

Join us for a free Zoom webinar hosted by the Prostate **Cancer Journal Club for Patients (PCJCP)**. We will dive into a groundbreaking study comparing different biopsy approaches.

The study randomized biopsy patients between three groups:

- Multi-Parametric MRI and conventional ultrasound-guided biopsy (the current standard).
- Micro-Ultrasound guided biopsy without MRI.
- MRI combined with micro-ultrasound guided biopsy.

We will also discuss the potential for future 'real-time' biopsy decisions using micro-ultrasound, which could enable same-visit biopsies if warranted, should the patient choose to proceed.

When: January 15, 2026 at 9:00 AM PT / 12:00 PM ET

Presented by: Adam Kinnaird, MD, PHD (University of Alberta); Laurence Klotz, MD (Sunnybrook Health Center)

Discussant: Geoff Sonn, MD (Stanford University)

Moderated by: Matthew Cooperberg, MD, MPH (UCSF)

Hosted by: UroToday, The Prostate Cancer Foundation, and UCSF Patient Advocates

Register for the Webinar Here: [Micro-Ultrasound Webinar Registration](#)

About the Prostate Cancer Journal Club for Patients

The PCJCP bridges the gap between complex medical research and patient care. We break down the latest "game-changing" clinical papers into clear, jargon-free insights, focusing specifically on how new findings directly impact your treatment options.

Our Mission: To empower patients with the knowledge needed to make informed decisions and engage in more effective, collaborative conversations with their medical teams.

This is our fifth PCJCP webinar. You can explore the recordings of our previous sessions below:

| Webinar Topic | Webinar recording | Patient Q&A Recording |
|---|---|-------------------------|
| A 15-year randomized trial comparing surgery, radiation, and active surveillance | Presentation and Discussion | Q&A |
| Effectiveness and side effects of treatment options for men with high-risk disease and rapidly rising PSA after primary therapy: (1) ADT monotherapy, (2) Enzalutamide monotherapy, (3) Combined Enzalutamide and ADT | Presentation and Discussion | Q&A |
| 'Unfavorable Histology' Classification Aims to Reduce Unnecessary Treatment | Presentation and Discussion | Q&A |
| Discussion Between Expert Clinicians and Patients: Comparing Traditional Risk Groups vs AI Analysis in Prostate Cancer Management | Presentation not yet available | Q&A |